View ValuationIndo Acidatama 将来の成長Future 基準チェック /06現在、 Indo Acidatamaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Chemicals 収益成長-44.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesRecent Insider Transactions • Jun 06Vice President Director recently bought Rp962m worth of stockOn the 3rd of June, Mulyadi Utomo Moeljono bought around 15m shares on-market at roughly Rp62.13 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth Rp1.3b. Mulyadi Utomo has been a buyer over the last 12 months, purchasing a net total of Rp2.4b worth in shares.Upcoming Dividend • May 26Upcoming dividend of Rp1.10 per shareEligible shareholders must have bought the stock before 02 June 2026. Payment date: 22 June 2026. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of Indonesian dividend payers (6.5%). Higher than average of industry peers (0.8%).Recent Insider Transactions • May 25Vice President Director recently bought Rp1.3b worth of stockOn the 20th of May, Mulyadi Utomo Moeljono bought around 19m shares on-market at roughly Rp65.99 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Mulyadi Utomo's only on-market trade for the last 12 months.お知らせ • May 22PT Indo Acidatama Tbk announces Annual dividend, payable on June 22, 2026PT Indo Acidatama Tbk announced Annual dividend of IDR 1.1000 per share payable on June 22, 2026, ex-date on June 02, 2026 and record date on June 03, 2026.Reported Earnings • May 05First quarter 2026 earnings released: EPS: Rp4.80 (vs Rp1.62 in 1Q 2025)First quarter 2026 results: EPS: Rp4.80 (up from Rp1.62 in 1Q 2025). Revenue: Rp239.5b (down 23% from 1Q 2025). Net income: Rp28.9b (up 197% from 1Q 2025). Profit margin: 12% (up from 3.1% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth.Recent Insider Transactions • May 01President Commissioner recently sold Rp13b worth of stockOn the 28th of April, Biantoro Setijo sold around 184m shares on-market at roughly Rp70.15 per share. This transaction amounted to 37% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of Rp39b more than they bought in the last 12 months.お知らせ • Apr 11PT Indo Acidatama Tbk, Annual General Meeting, May 19, 2026PT Indo Acidatama Tbk, Annual General Meeting, May 19, 2026.Reported Earnings • Apr 02Full year 2025 earnings released: EPS: Rp12.85 (vs Rp3.74 in FY 2024)Full year 2025 results: EPS: Rp12.85 (up from Rp3.74 in FY 2024). Revenue: Rp1.26t (up 8.9% from FY 2024). Net income: Rp77.4b (up 244% from FY 2024). Profit margin: 6.2% (up from 2.0% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Mar 31Investor sentiment improves as stock rises 19%After last week's 19% share price gain to Rp64.00, the stock trades at a trailing P/E ratio of 8x. Average trailing P/E is 13x in the Chemicals industry in Indonesia. Total returns to shareholders of 36% over the past three years.Reported Earnings • Nov 04Third quarter 2025 earnings released: EPS: Rp3.42 (vs Rp0.28 loss in 3Q 2024)Third quarter 2025 results: EPS: Rp3.42 (up from Rp0.28 loss in 3Q 2024). Revenue: Rp337.3b (up 9.5% from 3Q 2024). Net income: Rp20.6b (up Rp22.3b from 3Q 2024). Profit margin: 6.1% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.Board Change • Oct 24Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 10 highly experienced directors. 1 independent director (5 non-independent directors). Independent Commissioner FS Nusantara was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • May 10PT Indo Acidatama Tbk, Annual General Meeting, Jun 19, 2025PT Indo Acidatama Tbk, Annual General Meeting, Jun 19, 2025.Recent Insider Transactions • Aug 12Board Member recently bought Rp3.3b worth of stockOn the 8th of August, Shelumiel Setijo bought around 67m shares on-market at roughly Rp50.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought Rp8.2b more in shares than they have sold in the last 12 months.Recent Insider Transactions • Jun 26Vice President Director recently bought Rp480m worth of stockOn the 24th of June, Mulyadi Utomo Moeljono bought around 10m shares on-market at roughly Rp50.00 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Mulyadi Utomo has been a buyer over the last 12 months, purchasing a net total of Rp612m worth in shares.Recent Insider Transactions • Jun 08Vice President Director recently bought Rp30m worth of stockOn the 4th of June, Mulyadi Utomo Moeljono bought around 600k shares on-market at roughly Rp50.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Mulyadi Utomo has been a buyer over the last 12 months, purchasing a net total of Rp318m worth in shares.New Risk • Jun 05New major risk - Revenue and earnings growthEarnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.2% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (Rp301.0b market cap, or US$18.4m).お知らせ • May 19PT Indo Acidatama Tbk, Annual General Meeting, Jun 25, 2024PT Indo Acidatama Tbk, Annual General Meeting, Jun 25, 2024.Reported Earnings • May 04First quarter 2024 earnings released: EPS: Rp1.43 (vs Rp0.89 in 1Q 2023)First quarter 2024 results: EPS: Rp1.43 (up from Rp0.89 in 1Q 2023). Revenue: Rp228.2b (up 1.4% from 1Q 2023). Net income: Rp8.59b (up 60% from 1Q 2023). Profit margin: 3.8% (up from 2.4% in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Nov 29Investor sentiment improves as stock rises 16%After last week's 16% share price gain to Rp78.00, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 14x in the Chemicals industry in Indonesia. Total returns to shareholders of 42% over the past three years.Valuation Update With 7 Day Price Move • Nov 02Investor sentiment improves as stock rises 16%After last week's 16% share price gain to Rp64.00, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 13x in the Chemicals industry in Indonesia. Total returns to shareholders of 19% over the past three years.Reported Earnings • Aug 02Second quarter 2023 earnings released: EPS: Rp2.01 (vs Rp0.20 in 2Q 2022)Second quarter 2023 results: EPS: Rp2.01 (up from Rp0.20 in 2Q 2022). Revenue: Rp245.1b (up 10.0% from 2Q 2022). Net income: Rp12.1b (up Rp10.9b from 2Q 2022). Profit margin: 4.9% (up from 0.5% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 4% per year.Reported Earnings • Apr 08Full year 2022 earnings released: EPS: Rp5.59 (vs Rp4.41 in FY 2021)Full year 2022 results: EPS: Rp5.59 (up from Rp4.41 in FY 2021). Revenue: Rp977.7b (up 7.7% from FY 2021). Net income: Rp33.6b (up 27% from FY 2021). Profit margin: 3.4% (up from 2.9% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 9 highly experienced directors. 1 independent director (5 non-independent directors). Independent Commissioner FS Nusantara was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Aug 01Second quarter 2022 earnings released: EPS: Rp0.19 (vs Rp0.19 in 2Q 2021)Second quarter 2022 results: EPS: Rp0.19 (up from Rp0.19 in 2Q 2021). Revenue: Rp222.9b (up 11% from 2Q 2021). Net income: Rp1.18b (up 4.0% from 2Q 2021). Profit margin: 0.5% (down from 0.6% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Commissioner FS Nusantara was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Jan 21Investor sentiment improved over the past weekAfter last week's 27% share price gain to Rp70.00, the stock trades at a trailing P/E ratio of 13.4x. Average trailing P/E is 29x in the Chemicals industry in Indonesia. Total returns to shareholders of 17% over the past three years.Upcoming Dividend • Aug 11Upcoming dividend of Rp1.00 per shareEligible shareholders must have bought the stock before 18 August 2021. Payment date: 08 September 2021. Trailing yield: 3.6%. Lower than top quartile of Indonesian dividend payers (4.0%). Higher than average of industry peers (0.9%).Reported Earnings • Aug 09Second quarter 2021 earnings released: EPS Rp0.18 (vs Rp0.97 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: Rp200.1b (down 3.7% from 2Q 2020). Net income: Rp1.13b (down 81% from 2Q 2020). Profit margin: 0.6% (down from 2.8% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 4% per year.Reported Earnings • Jun 13Full year 2020 earnings released: EPS Rp7.33 (vs Rp7.11 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: Rp891.0b (up 30% from FY 2019). Net income: Rp44.2b (up 3.1% from FY 2019). Profit margin: 5.0% (down from 6.3% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Jan 28New 90-day low: Rp53.00The company is down 4.0% from its price of Rp55.00 on 27 October 2020. The Indonesian market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 23% over the same period.Is New 90 Day High Low • Dec 17New 90-day high: Rp62.00The company is up 15% from its price of Rp54.00 on 18 September 2020. The Indonesian market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 45% over the same period.Reported Earnings • Nov 28Third quarter 2020 earnings released: EPS Rp1.41The company reported a soft third quarter result with weaker earnings and profit margins, although revenues were improved. Third quarter 2020 results: Revenue: Rp200.6b (up 17% from 3Q 2019). Net income: Rp8.45b (down 29% from 3Q 2019). Profit margin: 4.2% (down from 7.0% in 3Q 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Indo Acidatama は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測IDX:SRSN - アナリストの将来予測と過去の財務データ ( )IDR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20261,183,45096,526332,959362,747N/A12/31/20251,256,36477,352220,822255,838N/A9/30/20251,299,03448,224122,805107,436N/A6/30/20251,269,85325,918-142,818-156,691N/A3/31/20251,238,04523,641-216,206-152,738N/A12/31/20241,153,78822,502-159,438-99,229N/A9/30/20241,083,46830,862-149,324-100,997N/A6/30/20241,056,26661,91524,99846,665N/A3/31/20241,029,84161,231-2,03915,270N/A12/31/20231,026,70558,01816,77136,607N/A9/30/20231,044,48776,137-3,71016,314N/A6/30/20231,035,35454,26829,58745,421N/A3/31/20231,013,12843,35449,91159,520N/A12/31/2022977,70833,64016,14624,091N/A9/30/2022899,61915,73577,59285,699N/A6/30/2022901,03519,50748,06657,470N/A3/31/2022878,27819,462146,107162,404N/A12/31/2021907,83326,54358,09076,374N/A9/30/2021959,23631,36950,55369,102N/A6/30/2021886,62428,578-22,48315,802N/A3/31/2021894,40833,302-176,228-132,822N/A12/31/2020890,99744,152-50,6515,784N/A9/30/2020808,40038,892-164,770-110,104N/A6/30/2020779,10842,405-72,773-36,383N/A3/31/2020725,09842,942-10,09721,099N/A12/31/2019683,57642,829N/A10,928N/A9/30/2019659,76138,525N/A21,008N/A6/30/2019652,50941,229N/A58,200N/A3/31/2019631,81643,903N/A82,463N/A12/31/2018600,98738,735N/A31,388N/A9/30/2018563,36039,677N/A52,039N/A6/30/2018522,48132,631N/A67,067N/A3/31/2018533,79426,449N/A79,966N/A12/31/2017521,48217,699N/A85,865N/A9/30/2017527,2848,061N/A161,416N/A6/30/2017486,341-1,810N/A103,838N/A3/31/2017492,4018,476N/A69,131N/A12/31/2016500,54011,056N/A114,822N/A9/30/2016537,31416,873N/A-11,925N/A6/30/2016558,89418,550N/A3,398N/A3/31/2016551,99612,112N/A19,775N/A12/31/2015531,57315,505N/A-76,733N/A9/30/2015485,9918,869N/A-35,683N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SRSNの予測収益成長が 貯蓄率 ( 6.7% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: SRSNの収益がID市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: SRSNの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: SRSNの収益がID市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: SRSNの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SRSNの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/30 22:46終値2026/06/30 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PT Indo Acidatama Tbk 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Recent Insider Transactions • Jun 06Vice President Director recently bought Rp962m worth of stockOn the 3rd of June, Mulyadi Utomo Moeljono bought around 15m shares on-market at roughly Rp62.13 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth Rp1.3b. Mulyadi Utomo has been a buyer over the last 12 months, purchasing a net total of Rp2.4b worth in shares.
Upcoming Dividend • May 26Upcoming dividend of Rp1.10 per shareEligible shareholders must have bought the stock before 02 June 2026. Payment date: 22 June 2026. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of Indonesian dividend payers (6.5%). Higher than average of industry peers (0.8%).
Recent Insider Transactions • May 25Vice President Director recently bought Rp1.3b worth of stockOn the 20th of May, Mulyadi Utomo Moeljono bought around 19m shares on-market at roughly Rp65.99 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Mulyadi Utomo's only on-market trade for the last 12 months.
お知らせ • May 22PT Indo Acidatama Tbk announces Annual dividend, payable on June 22, 2026PT Indo Acidatama Tbk announced Annual dividend of IDR 1.1000 per share payable on June 22, 2026, ex-date on June 02, 2026 and record date on June 03, 2026.
Reported Earnings • May 05First quarter 2026 earnings released: EPS: Rp4.80 (vs Rp1.62 in 1Q 2025)First quarter 2026 results: EPS: Rp4.80 (up from Rp1.62 in 1Q 2025). Revenue: Rp239.5b (down 23% from 1Q 2025). Net income: Rp28.9b (up 197% from 1Q 2025). Profit margin: 12% (up from 3.1% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth.
Recent Insider Transactions • May 01President Commissioner recently sold Rp13b worth of stockOn the 28th of April, Biantoro Setijo sold around 184m shares on-market at roughly Rp70.15 per share. This transaction amounted to 37% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of Rp39b more than they bought in the last 12 months.
お知らせ • Apr 11PT Indo Acidatama Tbk, Annual General Meeting, May 19, 2026PT Indo Acidatama Tbk, Annual General Meeting, May 19, 2026.
Reported Earnings • Apr 02Full year 2025 earnings released: EPS: Rp12.85 (vs Rp3.74 in FY 2024)Full year 2025 results: EPS: Rp12.85 (up from Rp3.74 in FY 2024). Revenue: Rp1.26t (up 8.9% from FY 2024). Net income: Rp77.4b (up 244% from FY 2024). Profit margin: 6.2% (up from 2.0% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Mar 31Investor sentiment improves as stock rises 19%After last week's 19% share price gain to Rp64.00, the stock trades at a trailing P/E ratio of 8x. Average trailing P/E is 13x in the Chemicals industry in Indonesia. Total returns to shareholders of 36% over the past three years.
Reported Earnings • Nov 04Third quarter 2025 earnings released: EPS: Rp3.42 (vs Rp0.28 loss in 3Q 2024)Third quarter 2025 results: EPS: Rp3.42 (up from Rp0.28 loss in 3Q 2024). Revenue: Rp337.3b (up 9.5% from 3Q 2024). Net income: Rp20.6b (up Rp22.3b from 3Q 2024). Profit margin: 6.1% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
Board Change • Oct 24Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 10 highly experienced directors. 1 independent director (5 non-independent directors). Independent Commissioner FS Nusantara was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • May 10PT Indo Acidatama Tbk, Annual General Meeting, Jun 19, 2025PT Indo Acidatama Tbk, Annual General Meeting, Jun 19, 2025.
Recent Insider Transactions • Aug 12Board Member recently bought Rp3.3b worth of stockOn the 8th of August, Shelumiel Setijo bought around 67m shares on-market at roughly Rp50.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought Rp8.2b more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Jun 26Vice President Director recently bought Rp480m worth of stockOn the 24th of June, Mulyadi Utomo Moeljono bought around 10m shares on-market at roughly Rp50.00 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Mulyadi Utomo has been a buyer over the last 12 months, purchasing a net total of Rp612m worth in shares.
Recent Insider Transactions • Jun 08Vice President Director recently bought Rp30m worth of stockOn the 4th of June, Mulyadi Utomo Moeljono bought around 600k shares on-market at roughly Rp50.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Mulyadi Utomo has been a buyer over the last 12 months, purchasing a net total of Rp318m worth in shares.
New Risk • Jun 05New major risk - Revenue and earnings growthEarnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.2% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (Rp301.0b market cap, or US$18.4m).
お知らせ • May 19PT Indo Acidatama Tbk, Annual General Meeting, Jun 25, 2024PT Indo Acidatama Tbk, Annual General Meeting, Jun 25, 2024.
Reported Earnings • May 04First quarter 2024 earnings released: EPS: Rp1.43 (vs Rp0.89 in 1Q 2023)First quarter 2024 results: EPS: Rp1.43 (up from Rp0.89 in 1Q 2023). Revenue: Rp228.2b (up 1.4% from 1Q 2023). Net income: Rp8.59b (up 60% from 1Q 2023). Profit margin: 3.8% (up from 2.4% in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Nov 29Investor sentiment improves as stock rises 16%After last week's 16% share price gain to Rp78.00, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 14x in the Chemicals industry in Indonesia. Total returns to shareholders of 42% over the past three years.
Valuation Update With 7 Day Price Move • Nov 02Investor sentiment improves as stock rises 16%After last week's 16% share price gain to Rp64.00, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 13x in the Chemicals industry in Indonesia. Total returns to shareholders of 19% over the past three years.
Reported Earnings • Aug 02Second quarter 2023 earnings released: EPS: Rp2.01 (vs Rp0.20 in 2Q 2022)Second quarter 2023 results: EPS: Rp2.01 (up from Rp0.20 in 2Q 2022). Revenue: Rp245.1b (up 10.0% from 2Q 2022). Net income: Rp12.1b (up Rp10.9b from 2Q 2022). Profit margin: 4.9% (up from 0.5% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 4% per year.
Reported Earnings • Apr 08Full year 2022 earnings released: EPS: Rp5.59 (vs Rp4.41 in FY 2021)Full year 2022 results: EPS: Rp5.59 (up from Rp4.41 in FY 2021). Revenue: Rp977.7b (up 7.7% from FY 2021). Net income: Rp33.6b (up 27% from FY 2021). Profit margin: 3.4% (up from 2.9% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 9 highly experienced directors. 1 independent director (5 non-independent directors). Independent Commissioner FS Nusantara was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 01Second quarter 2022 earnings released: EPS: Rp0.19 (vs Rp0.19 in 2Q 2021)Second quarter 2022 results: EPS: Rp0.19 (up from Rp0.19 in 2Q 2021). Revenue: Rp222.9b (up 11% from 2Q 2021). Net income: Rp1.18b (up 4.0% from 2Q 2021). Profit margin: 0.5% (down from 0.6% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Commissioner FS Nusantara was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Jan 21Investor sentiment improved over the past weekAfter last week's 27% share price gain to Rp70.00, the stock trades at a trailing P/E ratio of 13.4x. Average trailing P/E is 29x in the Chemicals industry in Indonesia. Total returns to shareholders of 17% over the past three years.
Upcoming Dividend • Aug 11Upcoming dividend of Rp1.00 per shareEligible shareholders must have bought the stock before 18 August 2021. Payment date: 08 September 2021. Trailing yield: 3.6%. Lower than top quartile of Indonesian dividend payers (4.0%). Higher than average of industry peers (0.9%).
Reported Earnings • Aug 09Second quarter 2021 earnings released: EPS Rp0.18 (vs Rp0.97 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: Rp200.1b (down 3.7% from 2Q 2020). Net income: Rp1.13b (down 81% from 2Q 2020). Profit margin: 0.6% (down from 2.8% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 4% per year.
Reported Earnings • Jun 13Full year 2020 earnings released: EPS Rp7.33 (vs Rp7.11 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: Rp891.0b (up 30% from FY 2019). Net income: Rp44.2b (up 3.1% from FY 2019). Profit margin: 5.0% (down from 6.3% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Jan 28New 90-day low: Rp53.00The company is down 4.0% from its price of Rp55.00 on 27 October 2020. The Indonesian market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 23% over the same period.
Is New 90 Day High Low • Dec 17New 90-day high: Rp62.00The company is up 15% from its price of Rp54.00 on 18 September 2020. The Indonesian market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 45% over the same period.
Reported Earnings • Nov 28Third quarter 2020 earnings released: EPS Rp1.41The company reported a soft third quarter result with weaker earnings and profit margins, although revenues were improved. Third quarter 2020 results: Revenue: Rp200.6b (up 17% from 3Q 2019). Net income: Rp8.45b (down 29% from 3Q 2019). Profit margin: 4.2% (down from 7.0% in 3Q 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.